Ongoing studies

Allogeneic transplantation for CLL – Olivier Tournilhac and Michel van Gelder

#2: AlloSCT after Multiple Pi (AMPi).
#3: AlloSCT after stopping Brutinib for intolerance or relapse (ASTIR).
#4: Venetoclax before and after alloSCT for CLL (VENAC).


The prognosis of Richter’s syndrome (RS) is very poor as a result of and resistance to salvage treatment and overall survival following Richter transformation is usually less than 1 year. In this context, both autologous and allogeneic transplantation are strategies that have been proposed and even recommended in consolidation when remission can be achieved. We propose to analyse transplantation in Richter syndrome, with the hope of determining prognostic factors predictive of evolution. We believe that this study is important given the recent development of BCR and BCL2L, and the emergence of Richter syndromes in this context.

T-cell prolymphocytic leukemia: autologous transplantation – Joanna Drozd-Sokolowska

T-cell prolymphocytic leukemia is a rare entity with poor prognosis. While alemtuzumab administered intravenously is considered a golden standard first line, yielding response in >90% patients, there is a strong need for both remission consolidation and effective treatment of relapse. There are many studies reporting on autologous HSCT for these indications. Although ASCT might not provide a cure to T-PLL patients, it might be a viable option for older, less fit patients. The aim of this study is to evaluate the outcomes of T-PLL patients receiving ASCT.

Hairy Cell Leukemia: autologous transplantation – Daj Chiara

Hairy cell leukemia (HCL) is an indolent B-cell neoplasm comprising 2% of leukemias. There remain continuous unmet needs for new treatment strategies particularly for relapsed/refractory HCL. This retrospective study aims to describe the clinical outcomes and evaluate the benefit of autologous HSCT in patients with HCL.

Most recent publications


Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation - study on behalf of CMWP of the EBMT – J. Drozd-Sokolowska et al. Bone Marrow Transplant. 2022 Feb 15. doi: 10.1038/s41409-022-01592-y.


Chronic Malignancies Working Party
CLL & PCD & PH&G
Activities of the working party and subcommittees
Chair: Ibrahim Yakoub-Agha
Secretary: Patrick Hayden
Email address: cmwpebmt@lumc.nl